@article{0cd96ba6c7094e58947228d53ff25da1,
title = "Comparison of {"}Word{"} vs. {"}Picture{"} version of the Free and Cued Selective Reminding Test (FCSRT) in older adults",
abstract = "Background: This study examined the psychometric relationship between the Word and Picture versions of the Free and Cued Selective Reminding Test (FCSRT) and developed an equation for score conversion. Methods: One hundred and eight-seven participants were administered the FCSRT-Picture and FCSRT-Word on two visits using a randomized counterbalanced design. Results: Participants had a mean age of 82.1 (standard deviation or SD=5.4) and mean education of 14.5 (SD=3.3) years. Mean FCSRT-Picture Free Recall score (mean 33.0 years, range: 17-44 years) was 7.9 points higher than the Word score (mean 25.1 years, range: 3-43 years). The Picture and Word FCSRT correlations for Free Recall and Total Recall were r=0.56, P<.01 and r=0.46, P<.01, respectively. Discussion: The Picture and Word versions of the FCSRT were moderately associated in a sample of cognitively normal older adults. The score mean differences and variability between FCSRT-Picture and FCSRT-Word indicate that their scores should not be considered equivalent.",
keywords = "Cognitive impairment, Dementia, Episodic memory, Free and Cued Selective Reminding Test, Older adults",
author = "Zimmerman, {Molly E.} and Katz, {Mindy J.} and Cuiling Wang and Burns, {Leah C.} and Berman, {Robert M.} and Derby, {Carol A.} and Gilbert L'Italien and David Budd and Lipton, {Richard B.}",
note = "Funding Information: The work presented in this article was supported by National Institutes of Health (NIH) grant AG03949 and an investigator-initiated grant from Bristol-Myers Squibb . Funding Information: M.E.Z., M.J.K., C.W., and C.A.D. are co-investigators on NIH AG003949. M.E.Z., M.J.K., and C.A.D. have received investigator-initiated research funding from Bristol-Myers Squibb . L.C.B., R.M.B., G.L., and D.B. are employees and shareholders of Bristol-Myers Squibb. R.B.L. receives research support from the NIH ( PO1 AG03949 [Program Director], PO1AG027734 [Project Leader], RO1AG025119 [Investigator], RO1AG022374-06A2 [Investigator], RO1AG034119 [Investigator], RO1AG12101 [Investigator], K23AG030857 [Mentor], K23NS05140901A1 [Mentor], and K23NS47256 [Mentor]), the National Headache Foundation , and the Migraine Research Fund ; serves on the editorial boards of Neurology and Cephalalgia and as senior advisor to Headache, has reviewed for the NIA and NINDS, holds stock options in eNeura Therapeutics (a company without commercial products); serves as consultant, advisory board member, or has received honoraria from: Allergan, American Headache Society, Autonomic Technologies, Boston Scientific, Bristol Myers Squibb, Cognimed, Colucid, Electrocore, Eli Lilly, eNeura Therapeutics, GlaxoSmithKline, Merck, Nautilus Neuroscience, Novartis, NuPathe, Vedanta, and Zogenix. Publisher Copyright: {\textcopyright} 2015 The Authors. Copyright: Copyright 2015 Elsevier B.V., All rights reserved.",
year = "2015",
doi = "10.1016/j.dadm.2014.11.006",
language = "English (US)",
volume = "1",
pages = "94--100",
journal = "Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring",
issn = "2352-8729",
publisher = "Elsevier BV",
number = "1",
}